C/O Bridgebio Pharma, Inc., 3160 Porter Drive, Suite 250, Palo Alto, CA
Summary
The estimated value of insider holdings of BridgeBio Pharma LLC is at least $167M dollars as of October 16, 2025. BridgeBio Pharma LLC is the 10%+ Owner of BridgeBio Oncology Therapeutics, Inc. and owns shares of Helix Acquisition Corp. II (HLXB) stock worth about $167M.
Signature
/s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC
Insider Transactions Reported by BridgeBio Pharma LLC:
Sym
Company
Class
Transaction
%
Value $
* Price $
Shares
Shares After
Date
Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.